Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-Vrd) in Transplant-Eligible (TE) Patients with Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (Hrcas)

Meletios A. Dimopoulos,Pieter Sonneveld,Paula Rodriguez-Otero,Hang Quach,P. Joy Ho,Meral Beksac,Cyrille Hulin,Elisabetta Antonioli,Xavier Leleu,Silvia Mangiacavalli,Aurore Perrot,Michele Cavo,Angelo Belotti,Annemiek Broijl,Francesca Gay,Roberto Mina,Inger S. Nijhof,Niels W. C. J. van de Donk,Eirini Katodritou,Fredrik Schjesvold,Anna Sureda Balari,Laura Rosinol,Michel Delforge,Wilfried Roeloffzen,Christoph Driessen,Annette Vangsted,Hermann Einsele,Andrew Spencer,Roman Hajek,Artur Jurczyszyn,Sarah Lonergan, Yanfang Liu, Jianping Wang,Diego Vieyra,Emilie M. J. van Brummelen,Veronique Vanquickelberghe,Anna Sitthi-Amorn,Carla J. de Boer,Robin Carson,Joan Blade,Mario Boccadoro,Philippe Moreau

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2024）

Cited 0|Views2
Key words
MM,multiple myeloma,CD38,minimal residual disease,cytogenetic abnormalities,daratumumab,phase 3
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined